WCN25-2290 EFFICACY OF INDUCTION TREATMENT WITH CYCLOPHOSPHAMIDE, RITUXIMAB AND THEIR COMBINATION IN PATIENTS WITH PAUCIIMMUNE VASCULITIS

WCN25-2290 EFFICACY OF INDUCTION TREATMENT WITH CYCLOPHOSPHAMIDE, RITUXIMAB AND THEIR COMBINATION IN PATIENTS WITH PAUCIIMMUNE VASCULITIS

Saved in:

Bibliographic Details
Main Authors:	Martín Benjamín Yamá Estrella, Mayra Matías Carmona, José Horacio Cano Cervantes, Carolina González Fuentes, Nicte Alaide Ramos García, Manuel Camacho Luna, Michelle Sánchez Maure, Fani Guadalupe Ruiz Rivera, Mario Eduardo Alamilla Sanchez
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924024227
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN24-1350 PAUCIIMMUNE ANCA (-) EXTRACAPILLARY GLOMERULONEPHRITIS IN A PATIENT WITH SLE
by: Enrique Fleuvier Morales López, et al.
Published: (2024-04-01)

Combination Cyclophosphamide and Rituximab to Minimize Glucocorticoid Use in Antineutrophil Cytoplasm Antibody–Associated Vasculitis
by: Tania Salehi, et al.
Published: (2025-07-01)

WCN24-781 COLISTIN-INDUCED ACUTE TUBULAR DYSFUNCTION, ELECTROLYTE IMBALANCES AND ASSOCIATED RENAL OUTCOMES
by: Martin Benjamin Yama Estrella, et al.
Published: (2024-04-01)

WCN24-673 COMPARISON OF HISTOLOGICAL RESULTS AND COMPLICATIONS ASSOCIATED WITH RENAL GRAFT BIOPSIES ACCORDING TO THEIR INDICATION
by: Martín Benjamín Yamá Estrella, et al.
Published: (2024-04-01)

Response to Rituximab after Failure of Cyclophosphamide in the Induction Treatment in a Patient with cANCA-associated Vasculitis and Pachymeningitis: a Case Report
by: O. Psenak, et al.
Published: (2021-08-01)

Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide
by: Marcelo Derbli Schafranski, et al.
Published: (2010-01-01)

Combination Induction Immunosuppression With Rituximab, Cyclophosphamide, and Prednisone for Fibrillary Glomerulonephritis
by: Gabriel Sauvage, et al.
Published: (2025-03-01)

WCN25-1475 PERCUTANEOUS RENAL BIOPSY IN SMALL KIDNEYS: A USEFUL AND SAFE PROCEDURE
by: Martín Benjamín Yamá Estrella, et al.
Published: (2025-02-01)

Combination Therapy With Rituximab and Low-Dose Cyclophosphamide and Prednisone in Membranous Nephropathy
by: Coralien H. Vink, et al.
Published: (2024-12-01)

Splenectomy following rituximab and cyclophosphamide for severe autoimmune hemolytic anemia in pregnancy
by: Tao Wang, et al.
Published: (2025-12-01)

Checkpoint inhibitor-related renal vasculitis and use of rituximab
by: Noha Abdel-Wahab, et al.
Published: (2020-10-01)

WCN24-2290 A novel approach to induce early remission in high-risk primary membranous nephropathy
by: Vladimir Dobronravov, et al.
Published: (2024-04-01)

Obinutuzumab in Rituximab-Intolerant Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Patients
by: Jolijn R. van Leeuwen, et al.
Published: (2025-04-01)

A Case of Polyarteritis Nodosa Associated with Vertebral Artery Vasculitis Treated Successfully with Tocilizumab and Cyclophosphamide
by: Kae Watanabe, et al.
Published: (2016-01-01)

Comparison of rituximab vs. cyclophosphamide in rheumatoid arthritis-associated interstitial lung disease and its correlation with spirometry
by: Mohammed Abdullah Saleem, et al.
Published: (2024-12-01)

Inferior Outcomes of Fludarabine–Cyclophosphamide–Rituximab Chemotherapy in Korean Chronic Lymphocytic Leukemia Patients with Concurrent Thrombocytopenia and Anemia
by: Tong-Yoon Kim, et al.
Published: (2025-01-01)

Ten-year experience with rituximab for induction and maintenance therapy in patients with ANCA-associated systemic vasculitis
by: T. V. Beketova, et al.
Published: (2020-03-01)

Case Report: Dual immunomodulatory and hematologic benefits of rituximab in refractory anemia of ANCA-associated vasculitis
by: Ningjun Shao, et al.
Published: (2025-08-01)

A multicenter retrospective study on comparing the efficacy and safety of the therapy of intermittent cyclophosphamide and corticosteroids versus rituximab for primary membranous nephropathy
by: Yi Wang, et al.
Published: (2024-12-01)

Ocular Manifestations of COVID-19 in a Patient with ANCAAssociated Vasculitis Treated with Rituximab. A Case Report
by: M. D. Suprun, et al.
Published: (2022-07-01)

HCV related severe cryoglobulinemic vasculitis treated with plasma exchange and rituximab: case report and literature review
by: Snezana Arandjelovic, et al.
Published: (2017-06-01)

Late-onset neutropenia induced by anti-B cell therapy with rituximab in patients with ANCA-associated systemic vasculitis
by: T. V. Beketova, et al.
Published: (2022-06-01)

Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)
by: T. V. Beketova, et al.
Published: (2020-09-01)

Rituximab in relapsed/refractory antineutrophil cytoplasmic antibody associated vasculitis: A single-center prospective observational study
by: Ekbote Gayatri, et al.
Published: (2019-01-01)

Cyclophosphamide: An Overview
by: Aditya Kumar Bubna
Published: (2025-01-01)

Combination therapy of rituximab and mycophenolate in patients with systemic sclerosis and primary cardiac involvement refractory to cyclophosphamide: a retrospective exploratory analysis of 10 cases
by: Gabriela Riemekasten, et al.
Published: (2025-06-01)

WCN25-2494 SURPRISINGLY GOOD RESPONSE OF A SEVERE ANCA-NEGATIVE CRESCENTIC PAUCI-IMMUNE GLOMERULONEPHRITIS SUCCESSFULLY TREATED WITH CORTICOSTEROIDS, CYCLOPHOSPHAMIDE AND RITUXIMAB
by: Eleni Theodoropoulou, et al.
Published: (2025-02-01)

Efficacy and Long-Term Outcomes of Tacrolimus versus Cyclophosphamide and Mycophenolate Mofetil in the Management of Pediatric IgA Vasculitis Nephritis: A Cohort Study in Single-Center
by: Han Y, et al.
Published: (2025-07-01)

Long-term maintenance of remission with spacing of rituximab infusions based on the individualised patient risk profile in ANCA-associated vasculitis: a pilot study
by: Carlomaurizio Montecucco, et al.
Published: (2025-06-01)

WCN25-3095 LONG-TERM RESULTS OF TREATMENT WITH DIRECT ACTING ANTIVIRALS, CORTICOSTEROIDS, PLASMAPHERESIS AND RITUXIMAB IN A PATIENT WITH CRYOGLOBULINEMIC VASCULITIS AND HCV INFECTION
by: Eleni Theodoropoulou, et al.
Published: (2025-02-01)

The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic
by: T. V. Beketova, et al.
Published: (2021-03-01)

Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas
by: Simon Bond, et al.
Published: (2024-07-01)

Vasculitis
by: María Inés Muñoz, et al.
Published: (2025-04-01)

Vasculitis IgA en el adulto. Informe de caso
by: Samuel Sánchez Sánchez, et al.
Published: (2021-02-01)

WCN24-1259 HISTOLOGICAL FINDINGS, CLINICAL CHARACTERISTICS AND SHORT-TERM COURSE IN DIABETIC PATIENTS SUBJECTED TO RENAL BIOPSY, EXPERIENCE IN A SINGLE CENTER
by: Francisco Javier Hernandez Copca, et al.
Published: (2024-04-01)

Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results
by: T. V. Beketova, et al.
Published: (2024-11-01)

Cyclophosphamide-induced nail pigmentation: An uncommon presentation
by: Deepthi Konda, et al.
Published: (2025-01-01)

Intra Arterial Infusion of Cyclophosphamide in Oral Carcinoma
by: N. C. Misra, et al.
Published: (1970-12-01)

Safety of Cyclophosphamide Therapy in Autoimmune Rheumatic Diseases
by: Ramaswamy Subramanian, et al.
Published: (2019-01-01)

High Dose Cyclophosphamide Treatment for Autoimmune Disorders
by: Robert A. Brodsky
Published: (2002-01-01)